Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04141 (
granulocyte-macrophage colony-stimulating factor
)
6,790
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In this study, we analyzed the expression and function of the lymphocyte surface lectin
NKRP1A
on peripheral blood monocytes (Mo) or Mo and dendritic cells (DC) derived from thymic and bone marrow precursors. De novo expression of
NKRP1A
and CD14 molecules was detected upon culture of CD2- CD3- CD14- CD16- CD1a-
NKRP1A
- immature thymic precursors for 7 days in the presence of
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
). Under these culture conditions, by day 21, a fraction of cells had lost CD14 and acquired both CD80 (B7.1) and CD86 (B7.2) molecules. These cells displayed a DC-like morphology and were surface
NKRP1A
positive. CD34+
NKRP1A
- CD14- precursors, isolated from bone marrow and cultured in the presence of
GM-CSF
, also expressed both
NKRP1A
and CD14: these antigens were newly expressed on about one third of cells which had lost the CD34 precursor marker. In addition,
NKRP1A
was constitutively present on resting CD14+ peripheral blood Mo. When these cells were cultured in the presence of
GM-CSF
, the resulting DC population retained the expression of
NKRP1A
and acquired CD80, while they lost the CD14 antigen. Functional analysis revealed that the engagement of
NKRP1A
molecule leads to a strong intracellular calcium ([Ca2+]i) increase both in resting peripheral blood Mo and in vitro-derived DC. [Ca2+]i increase was mainly due to extracellular calcium influx, as it was completely abrogated by the addition of EGTA. More importantly, the engagement of the
NKRP1A
molecule induced interleukin (IL)-1 beta and IL-12 production by resting Mo and DC, respectively. Altogether these data indicate that
NKRP1A
lectin is present at the surface of Mo and DC and may play a relevant role in the activation and function of both cell types.
...
PMID:Expression and function of NKRP1A molecule on human monocytes and dendritic cells. 939 25
Human T cells expressing
CD161
and an invariant T-cell receptor (TCR) alpha-chain (Valpha24invt T cells) specifically recognize CD1d and appear to have immunoregulatory functions. However, the physiological target cells for this T-cell population, and whether alterations in CD1d expression contribute to the regulation of Valpha24invt T-cell responses, remain to be determined. A series of antibodies were generated to assess CD1d expression, structure and regulation on human lymphoid and myeloid cells. CD1d was expressed at high levels by human cortical thymocytes and immunoprecipitation analyses showed it to be a 48 000-MW glycosylated protein. However, after solubilization, the majority of the thymocyte CD1d protein, but not CD1d expressed by transfected cells, lost reactivity with monoclonal antibodies (mAbs) against native CD1d, indicating that it was alternatively processed. Moreover, thymocytes were not recognized by CD1d-reactive Valpha24invt T-cell clones. Medullary thymocytes and resting peripheral blood T cells were CD1d-, but low-level CD1d expression was induced on activated T cells. CD1d was expressed by B cells in peripheral blood and lymph node mantle zones, but germinal centres were CD1d-. Resting monocytes were CD1d+ but, in contrast to CD1a, b and c, their surface expression of CD1d was not up-regulated by
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) and interleukin-4 (IL-4) activation. These results demonstrate constitutive CD1d expression by human professional antigen-presenting cells and that post-translational processing of CD1d may contribute to regulation of the activity of CD1d-specific T cells.
...
PMID:CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. 1080 57